In contrast to previous findings from our group [6] and others [7] in mouse models of obesity and type 2 diabetes, we observed little change in beta cell function after IL-22 therapy in the NOD mouse. The gene discussed is IL22; the disease is obesity due to melanocortin 4 receptor deficiency.